NCT07120152View on ClinicalTrials.gov

A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease

Not yet recruitingOBSERVATIONAL
Enrollment

439

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 1, 2026

Study Completion Date

March 1, 2027

Conditions
IBD - Inflammatory Bowel DiseaseRA - Rheumatoid Arthritis
Interventions
DRUG

Subcutaneous infliximab CT-P13 Remsima®SC

Subcutaneous infliximab

All Listed Sponsors
collaborator

San Raffaele University Hospital, Italy

OTHER

collaborator

University of Liverpool

OTHER

collaborator

Hospital Universitario La Fe

OTHER

collaborator

University of Southampton

OTHER

collaborator

Samsung Medical Center

OTHER

lead

Erwin Dreesen

OTHER

NCT07120152 - A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease | Biotech Hunter | Biotech Hunter